Evonik Industries and Rottendorf Pharma cooperate in full-service melt-extrusion technology deal
Rottendorf Pharma GmbH, one of the leading contract manufacturers of pharmaceuticals in Europe, which develops, manufactures, and packages fixed dosage forms, has recently introduced a new development and upscaling center at the company headquarters in Ennigerloh. The 2,400-square-meter pilot plant not only spans the entire range of production technologies for solids, but also possesses innovative melt extrusion technology—through a cooperative deal with Evonik Industries.
“Over the last 10 years, we’ve been building up a high level of development expertise that allows us to carry out development projects requested by pharmaceuticals companies,” states Dr. Christian Thülig, regional marketing manager for Pharma Polymers at Evonik. Working together, Evonik and Rottendorf cover the entire development span —from early pharmaceutical development to production. “The focus is on processing active ingredients with low solubility,” adds Dr. Stephan Fleck, managing director of the Rottendorf Group.
“Customers benefit from our know-how, shorter development times, and low development and production costs,” stresses Andreas Gryczke, who was responsible for building up Evonik‘s melt extrusion capabilities.
Melt extrusion is a continuous process for mixing and producing molding compounds. This process is already known in the polymer and food industries and is also being used in the production of pharmaceuticals, thanks to its economical and environmentally friendly qualities and the potential to develop innovative new formulations.
Evonik Industries is a creative industrial concern headquartered in Germany with Chemicals, Energy and Real Estate Business Areas. Evonik is one of the leading companies in the world in specialty chemicals and an expert in generating electricity from hard coal and renewable energies, as well as one of the largest private residential real estate companies in Germany. Creativity, expertise, continual self-renewal, and reliability are our strengths. Evonik is active in more than 100 countries. About 41,000 employees generated sales revenues of about EUR 15.9 billion and operating profits (EBITDA) of about EUR 2.2 billion in fiscal year 2008.
To the extent we make forecasts or express our expectations in this press release or our statements relate to the future, the forecasts or expectations expressed may be associated with known or unknown risks and uncertainties. Actual results or developments may differ based on changes in general conditions. Neither Evonik Industries AG nor its affiliates assumes any obligation to update the forecasts, expectations, or statements contained in this press release.